146 related articles for article (PubMed ID: 38307919)
21. S100A10 Is a New Prognostic Biomarker Related to the Malignant Molecular Features and Immunosuppression Process of Adult Gliomas.
Ma K; Chen S; Chen X; Yang C; Yang J
World Neurosurg; 2022 Sep; 165():e650-e663. PubMed ID: 35779750
[TBL] [Abstract][Full Text] [Related]
22. Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas.
Zhu P; Zhang CB; Yang P; Chen J; Liu YQ; Hu HM; Huang H; Bao ZS; Zhang W; Kong WJ; Jiang T
Oncotarget; 2016 Jul; 7(29):45005-45014. PubMed ID: 27323851
[TBL] [Abstract][Full Text] [Related]
23. Experimental validation of 5 in-silico predicted glioma biomarkers.
Towner RA; Jensen RL; Vaillant B; Colman H; Saunders D; Giles CB; Wren JD
Neuro Oncol; 2013 Dec; 15(12):1625-34. PubMed ID: 24158112
[TBL] [Abstract][Full Text] [Related]
24. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas.
Luo C; Liu Z; Ye W; Liu F
Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164
[No Abstract] [Full Text] [Related]
25. Integrative analysis of TP73 profile prognostic significance in WHO grade II/III glioma.
Chen Y; Wang Y; He Q; Wang W; Zhang T; Wang Z; Dong J; Lan Q; Zhao J
Cancer Med; 2021 Jul; 10(13):4644-4657. PubMed ID: 34121368
[TBL] [Abstract][Full Text] [Related]
26. Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis.
Zeng C; Song X; Zhang Z; Cai Q; Cai J; Horbinski C; Hu B; Cheng SY; Zhang W
Acta Neuropathol Commun; 2023 Aug; 11(1):133. PubMed ID: 37580817
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of MEOX2 in gliomas.
Tachon G; Masliantsev K; Rivet P; Petropoulos C; Godet J; Milin S; Wager M; Guichet PO; Karayan-Tapon L
Mod Pathol; 2019 Jun; 32(6):774-786. PubMed ID: 30659268
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.
Hou C; Ishi Y; Motegi H; Okamoto M; Ou Y; Chen J; Yamaguchi S
J Neurooncol; 2019 Nov; 145(2):201-210. PubMed ID: 31506754
[TBL] [Abstract][Full Text] [Related]
29. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
[TBL] [Abstract][Full Text] [Related]
30. Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses.
Yuan F; Yi L; Hai L; Wang Y; Yang Y; Li T; Tong L; Ma H; Liu P; Ming H; Ren B; Yu S; Lin Y; Yang X
Dis Markers; 2019; 2019():7049294. PubMed ID: 31772693
[TBL] [Abstract][Full Text] [Related]
31. Computational analysis of the mesenchymal signature landscape in gliomas.
Celiku O; Tandle A; Chung JY; Hewitt SM; Camphausen K; Shankavaram U
BMC Med Genomics; 2017 Mar; 10(1):13. PubMed ID: 28279210
[TBL] [Abstract][Full Text] [Related]
32. BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas.
Bao Z; Zhang C; Yan W; Liu Y; Li M; Zhang W; Jiang T
J Transl Med; 2013 Apr; 11():100. PubMed ID: 23590708
[TBL] [Abstract][Full Text] [Related]
33. Genomics and Prognosis Analysis of Epithelial-Mesenchymal Transition in Glioma.
Tao C; Huang K; Shi J; Hu Q; Li K; Zhu X
Front Oncol; 2020; 10():183. PubMed ID: 32154177
[No Abstract] [Full Text] [Related]
34. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
35. Basement-Membrane-Related Gene Signature Predicts Prognosis in WHO Grade II/III Gliomas.
Zhang Z; Lai G; Sun L
Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292695
[TBL] [Abstract][Full Text] [Related]
36. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
37. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
38. Immunological classification of gliomas based on immunogenomic profiling.
Feng Q; Li L; Li M; Wang X
J Neuroinflammation; 2020 Nov; 17(1):360. PubMed ID: 33246490
[TBL] [Abstract][Full Text] [Related]
39. Input of molecular analysis in medical management of primary brain tumor patients.
Idbaih A; Duran-Peña A; Bonnet C; Ducray F
Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
[TBL] [Abstract][Full Text] [Related]
40. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]